Organization
Mario Negri Institute for Pharmacological Research
25 clinical trials
1 abstract
Clinical trial
A Multicenter, Open-label Phase II Trial of a New Customized Dosing (RADAR Dosing) of Niraparib as Maintenance Therapy in Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Recurrent Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
BRIDGE Trial: Phase II Trial of durvalumaB and chemotheRapy Induction Followed by Durvalumab and Radiotherapy in larGe volumE Stage III NSCLCStatus: Active (not recruiting), Estimated PCD: 2026-06-01
Clinical trial
Basiliximab With One Day or Seven Days RATG Induction Therapy in Renal Transplantation: a Matched-cohort Observational StudyStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Obinutuzumab for Primary Membranous Nephropathy: a Pilot Study in Patients With Rituximab-resistant or Rituximab-dependent Nephrotic Syndrome and in Patients Intolerant to Rituximab (the ORION Study)Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Randomized Phase 2 Clinical Trial to Evaluate the Activity of ATRA in Combination With Anastrozole in Pre-operative Phase of Operable HR-positive/HER2-negative Early Breast Cancer (ATRA)Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Prospective, Double-blind, Randomized, Single Centre Trial to Evaluate the Rate of RAAS Inhibitor Withdrawal or Down-titration in Non-dialysis Patients With CKD Stage IIIb to V Randomized to Patiromer or Placebo (DROP)Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledronate and Atorvastatin in Triple Negative Breast Cancers - YAPPETIZER StudyStatus: Completed, Estimated PCD: 2021-06-17
Clinical trial
Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group TrialStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant ToleranceStatus: Terminated, Estimated PCD: 2013-07-01
Clinical trial
Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Prophylactic Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC CO2) Versus Standard Surgery in Colorectal Carcinoma at High Risk Peritoneal Carcinomatosis. Short and Long-term Outcomes. CHECK STUDYStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase II Study on Trabectedin in Combination With PPARg Agonist Pioglitazone in Patients With Round Cell Myxoid Liposarcomas or Dedifferentiated G1 and G2 Liposarcomas With Stable Disease After a Monotherapy With Trabectedin. (TRABEPIO)Status: Recruiting, Estimated PCD: 2024-12-02
Clinical trial
Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Rescue Therapy With the Human Anti-CD38 Antibody MOR202 (Felzartamab) in Patients With Membranous Nephropathy Who Failed Anti-CD20 Target TherapyStatus: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
A Phase IV Trial to Confirm the Efficacy of Olaparib in Combination With Bevacizumab as Frontline Treatment of HRD Positive Ovarian TumorsStatus: Recruiting, Estimated PCD: 2027-03-15
Clinical trial
Prevention of Hospitalization of Patients With Early COVID-19 by an Anti-inflammatory Drug-based Home-treatment Algorithm:a Three-months, Pragmatic, Cluster Randomized, Open-label, Blinded Endpoint (PROBE) TrialStatus: Withdrawn, Estimated PCD: 2024-02-06
Clinical trial
Evaluating Baseline Predictors Including Total Kidney Volume, of Chronic GFR Decline and Other Clinical Outcomes in Outpatients With ADPKD and Stage IV CKD on Chronic Treatment With Octreotide LAR: a Retrospective, Observational StudyStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport SyndromeStatus: Completed, Estimated PCD: 2008-06-01
Clinical trial
Familiar Fatal Insomnia: Preventive Treatment With Doxycycline in Subject With Disease RiskStatus: Completed, Estimated PCD: 2021-04-12
Clinical trial
Autologous Mesenchymal Stromal Cells to Induce Tolerance in Living-donor Kidney Transplant RecipientsStatus: Terminated, Estimated PCD: 2023-05-29
Clinical trial
A Simple, Home-treatment Algorithm to Prevent Hospitalization for COVID-19 Patients: A Matched -Cohort StudyStatus: Completed, Estimated PCD: 2021-12-21
Clinical trial
A Phase II Study to Investigate the Activity and Safety of Anti-PD-L1 Antibody (Durvalumab) In ADvancEd Pretreated Malignant Pleural Mesothelioma - DIADEM StudyStatus: Completed, Estimated PCD: 2019-05-16
Clinical trial
A Phase III Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer _ CANAL StudyStatus: Terminated, Estimated PCD: 2022-04-03
Clinical trial
A Randomized, Phase II/III Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALSStatus: Not yet recruiting, Estimated PCD: 2026-04-01
Abstract
Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).Org: Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,